Sign In
Buy PTCT
$82.13
+1.17 (+1.45%)
At Close: Jun 23, 2026
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 13'th Jan 2021
SOUTH PLAINFIELD, N.J., Jan. 13, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggregate of
PTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39th Annual J.P. Morgan Healthcare Conference
06:30am, Monday, 11'th Jan 2021
SOUTH PLAINFIELD, N.J., Jan. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its R&D pipeline and commercial progress at the 39th Annual J.P. Morgan Healthcare
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 18'th Dec 2020
SOUTH PLAINFIELD, N.J., Dec. 18, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 15, 2020 it approved non-statutory stock options to purchase an aggregate o
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 04'th Dec 2020
SOUTH PLAINFIELD, N.J., Dec. 4, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 2, 2020 it approved non-statutory stock options to purchase an aggregate of
PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference
08:00am, Thursday, 19'th Nov 2020
SOUTH PLAINFIELD, N.J., Nov. 19, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at Evercore ISI 3rd Annual HealthCONx Confer
PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q3 2020 Results - Earnings Call Transcript
02:26am, Friday, 30'th Oct 2020
PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q3 2020 Results - Earnings Call Transcript
